QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...

 rani-therapeutics-holdings-files-for-mixed-shelf-offering-of-up-to-200m

-SEC Filing

 rani-therapeutics-hldgs-q2-eps-018-beats-024-estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate ...

 rani-therapeutics-unveils-data-on-robotic-pill-that-matches-injections-in-canine-study-at-endo-2025

Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutic...

 rani-therapeutics-holdings-announces-nasdaq-noncompliance-notice

-SEC Filing

 watching-rani-therapeutics-zacks-small-cap-research-gives-stock-12-price-valuation

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_05192025_RANI_Vandermosten.pdf

 oppenheimer-maintains-outperform-on-rani-therapeutics-hldgs-lowers-price-target-to-4

Oppenheimer analyst Andreas Argyrides maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Outperform and lowers the price...

 rani-therapeutics-hldgs-q1-eps-022-misses-021-estimate-sales-17200k

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION